Autopsy report · NCT02973295

Silymarin in NAFLD

“Sponsor withdrawn their agreement”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

University Hospital Rijeka

Sponsor type

University, hospital or other

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Silymarin; Placebo Oral Capsule

Participants

0

Sites

1

Countries

Croatia

Trials that died the same way

• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (88% match in meaning)
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
  “Withdrawn by sponsor” (87% match in meaning)
• Study of Atiprimod Treatment for Patients With Advanced Cancer
  “Sponsor Withdrew” (85% match in meaning)
• Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
  “Sponsor withdrew support” (84% match in meaning)
• Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads
  “Sponsor withdrew funding” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.